
Boehringer Ingelheim and UK biotech firm Oxford BioTherapeutics (OBT) have signed a deal to discover novel antibody targets in cancer. …
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions

